Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 30Rectal Neoplasms 21Esophageal Neoplasms 15Colorectal Neoplasms 15Pancreatic Neoplasms 12Lung Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Prostatic Neoplasms 10Adenocarcinoma Of Esophagus 9Stomach Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Head and Neck Neoplasms 8Sarcoma 7Esophageal Squamous Cell Carcinoma 7Neoplasms 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Intraductal, Noninfiltrating 5Urinary Bladder Neoplasms 4Inflammatory Breast Neoplasms 4Fallopian Tube Neoplasms 4Breast Neoplasms, Male 4Breast Carcinoma In Situ 4Brain Neoplasms 4Recurrence 3Neoplasm Metastasis 3Kidney Neoplasms 3Glioma 3Glioblastoma 3

Interventions

Gemcitabine 6Pemetrexed 3Cisplatin 3Carboplatin 3atezolizumab 2Trastuzumab 2Sugammadex 2Paclitaxel 2Neostigmine 2vinflunine 1poly ICLC 1pembrolizumab 1motexafin gadolinium 1montanide ISA 51 1flt3 ligand protein 1enfortumab vedotin 1delta 24-sterol reductase 1daratumumab 1avelumab 1apatorsen 1abemaciclib 1Water 1Thalidomide 1Surveys and Questionnaires 1Saline Solution 1Rocuronium 1Nephroureterectomy 1Nephrectomy 1Neoadjuvant Therapy 1Mitomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Urologic Neoplasms × Neoadjuvant Therapy × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔